Events & Presentations

Document	Type
Aug 07, 2018	Corporate Presentation 1.1 MB

More events are coming soon.

Date	Event Details	Remind Me
Aug 14, 2018 10:30 AM EDT	2018 Wedbush PacGrow Healthcare Conference listen to webcast
Aug 7, 2018 4:30 PM EDT	MACROGENICS, INC. SECOND QUARTER 2018 FINANCIAL RESULTS CONFERENCE CALL listen to webcast
Jun 3, 2018 9:00 AM EDT	Poster Presentation at ASCO Annual Meeting 2018 Supporting Materials Margetuximab + Pembrolizumab in ERBB2-amplified PD-L1+ Gastroesophageal Adenocarcinoma (GEA) Post Trastuzumab 521.2 KB A Phase 1, Open Label, Dose Escalation Study of MGD009 in Combination with MGA012 in Patients with Relapsed or Refractory B7-H3-expressing Tumors (TIP) 534.4 KB
May 7, 2018 4:30 PM EDT	MacroGenics, Inc. First Quarter 2018 Financial Results Conference Call listen to webcast
Apr 15, 2018 1:00 PM CDT	Presentation of Posters at 2018 AACR Annual Meeting Supporting Materials Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer 1.3 MB Immunotherapy of Colorectal Cancer by the T-cell Targeted DART® Protein MGD007: Cellular Mechanism of Action 1.9 MB
Feb 27, 2018 4:30 PM EST	MacroGenics, Inc. Fourth Quarter and Full Year 2017 Financial Results Conference Call listen to webcast Supporting Materials Corporate Presentation 1.5 MB
Feb 26, 2018 12:00 AM EST	Keystone Symposia (Antibodies as Drugs: Translating Molecules into Treatments): ”Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART Molecules for Redirected T-cell Killing” Supporting Materials View Presentation 895.9 KB
Jan 18, 2018 12:00 AM EST	Presentation of Margetuximab Clinical Data at 2018 ASCO GI Cancers Symposium Supporting Materials View Presentation 631.6 KB
Dec 9, 2017 5:30 PM EST	Presentations at 59th Annual ASH Meeting regarding Flotetuzumab (CD123 x CD3 Bispecific DART Protein) Supporting Materials Oral: Preliminary Results of Phase 1 Study in Patients with Relapsed/Refractory AML and MDS 899 KB Poster: Preliminary Results from Ongoing Phase 1 Study in AML/MDS: Rationale for Combining with Anti-PD-1/PD-L1 4.5 MB Poster: Lead-in Dose Optimization to Mitigate CRS in AML and MDS Patients 1 MB
Nov 10, 2017 12:00 AM EST	Data presented at SITC Annual Meeting 2017: Supporting Materials MGA012: Phase 1 Study of Safety, Tolerability, and PK of Anti-PD-1 Antibody in Patients with Advanced Solid Tumors 1.4 MB MGA012: Preclinical Characterization of Novel Clinical-stage PD-1 Monoclonal Antibody 1.2 MB MGD013: Phase 1 Dose Escalation Study of PD-1 x LAG-3 DART Molecule 1.6 MB MGD013: Preclinical Characterization of PD-1 x LAG-3 DART Molecule 1.6 MB MGD019: PD-1 x CTLA-4 DART Molecule with Optimal Dual Checkpoint Blockade and Favorable Tolerability 620.5 KB
Nov 8, 2017 4:30 PM EST	MacroGenics, Inc. Third Quarter 2017 Financial Results Conference Call Listen to webcast
Sep 10, 2017 5:00 AM EDT	Oral Presentation at ESMO 2017 Supporting Materials Interim Results from a Phase 1 First-in-Human Study of Flotetuzumab, a CD123 x CD3 Bispecific DART Molecule, in AML/MDS 474.8 KB
Jun 17, 2017 12:00 AM EDT	MacroGenics Presentation at the Annual European Congress of Rheumatology (EULAR 2016) Supporting Materials Immunomodulatory Effects of MGD010, a DART® Molecule Targeting Human B-cell CD32B and CD79B 824.1 KB
Jun 5, 2017 9:00 AM EDT	Trials-in-Progress Poster Presentation at ASCO Annual Meeting 2017 Supporting Materials A Phase 1, Open-label, Dose Escalation Study of MGA271 (Enoblituzumab) in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors 3.1 MB A Phase 1, First-in-Human Study of MGD006/S80880 (CD123 x CD3) in AML/MDS 2.5 MB
Apr 2, 2017 at 1:00 PM EDT to Apr 4, 2017 at 12:00 AM EDT	Presentation of eight posters at 2017 AACR Annual Meeting Supporting Materials Preclinical Development of a Duocarmycin-Based ADC Targeting B7-H3 for Solid Cancer 7.8 MB Target Validation, Antibody Discovery and Preclinical Data Supporting ADAM9 as ADC 7.9 MB Novel ADC Targeting ADAM9-expressing Solid Tumors Demonstrate Potent Preclin. Activity 2.4 MB Tumor-Antigen Expression-Dependent Activ. of CD137 Costim. Pathway by DART Proteins 2.3 MB Co-targeting PD-1 and CTLA-4 Inhibitory Pathways with DART and TRIDENT Molecules 1.8 MB Potent Antitumor Activity of Duvortuxizumab (CD19 x CD3 DART) in Lymphoma Models 3.5 MB Quant. Prediction of Human PK for Duvortuxizumab: a Translational PK Model. Approach 284.3 KB 5T4 x CD3 DART Molecule w/ Extended Half-life for T-cell Immunotherapy of Cancers 7.8 MB View Additional Information Preclinical Development of a Duocarmycin-Based ADC Targeting B7-H3 for Solid Cancer Target Validation, Antibody Discovery and Preclinical Data Supporting ADAM9 as ADC Novel ADC Targeting ADAM9-expressing Solid Tumors Demonstrate Potent Preclin. Activity Tumor-Antigen Expression-Dependent Activ. of CD137 Costim. Pathway by DART Proteins Co-targeting PD-1 and CTLA-4 Inhibitory Pathways with DART and TRIDENT Molecules Potent Antitumor Activity of Duvortuxizumab (CD19 x CD3 DART) in Lymphoma Models Quant. Prediction of Human PK for Duvortuxizumab: a Translational PK Model. Approach 5T4 x CD3 DART Molecule w/ Extended Half-life for T-cell Immunotherapy of Cancers
Jan 20, 2017 12:00 AM EST	Margetuximab TIP Poster Presentation at 2017 ASCO Gastrointestinal Cancers Symposium Supporting Materials MacroGenics 2017 ASCO GI Cancers TIP Poster 671.9 KB
Dec 13, 2016 8:30 AM EST	MacroGenics, Inc. R&D Day 2016 Listen to webcast Supporting Materials View Presentation 34.6 MB
Dec 7, 2016 12:00 AM EST	Margetuximab TIP Poster Presentation at San Antonio Breast Cancer Symposium 2016 Supporting Materials View Poster 1.7 MB
Jun 10, 2016 5:40 AM EDT	MacroGenics Presentation at the Annual European Congress of Rheumatology (EULAR 2016) Supporting Materials MGD010 (CD32B x CD79B DART Molecule) Phase 1 Clinical Data Presentation 2.3 MB
Jun 5, 2016 9:00 AM EDT	Trials-in-Progress Poster Presentation at ASCO Annual Meeting 2016 Supporting Materials Margetuximab Phase 3 SOPHIA Study (Abstract #164475) 1.1 MB Enoblituzumab in Combination with Pembrolizumab (Abstract #165034) 1.3 MB Dose Escalation Study of MGD009 (Abstract #165085) 3.8 MB Dose Escalation Study of MGD007 (Abstract #165517) 1.3 MB
Apr 17, 2016 at 2:00 PM EDT to Apr 19, 2016 at 12:00 AM EDT	Five Posters Presented at 2016 American Association for Cancer Research (AACR) Annual Meeting Supporting Materials EphA2 x CD3 bispecific Dual-Affinity Re-Targeting (DART) Molecule 3.2 MB ROR1 x CD3 bispecific DART Molecule 3.2 MB IL13Ralpha2 x CD3 bispecific DART Molecule 5 MB Anti-B7-H3 antibody-drug conjugates 6.5 MB MGD013, a bispecific PD-1 x LAG-3 DART Molecule 5.9 MB View Additional Information EphA2 x CD3 bispecific Dual-Affinity Re-Targeting (DART®) Molecule ROR1 x CD3 bispecific DART Molecule IL13Ralpha2 x CD3 bispecific DART Molecule Anti-B7-H3 antibody-drug conjugates MGD013, a bispecific PD-1 x LAG-3 DART Molecule
Mar 7, 2016 12:00 AM EST	Preclinical Data Presented at Keystone Symposia's Antibodies as Drugs (X2) Conference: MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors Supporting Materials View Presentation 4.8 MB
Saturday, May 30, 2015 8:00 am CDT	Data Presented at ASCO Annual Meeting 2015: <br> Updated findings of a first-in-human phase 1 study of margetuximab, an Fc-optimized chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors Supporting Materials View Presentation 1 MB View Additional Information Location: S Hall A Poster Board Number: 11 Abstract Number: 523 Presented by: Howard A. Burris, M.D.
Monday, Apr 20, 2015 1:00 pm EDT	Preclincal Data Presented at AACR Annual Meeting 2015:<br> DART® molecules with enhanced DR5 agonistic activity for improved cancer cell cytotoxicity Supporting Materials View Presentation 6.4 MB View Additional Information Location: Poster section 25 Poster Board Number: 6 Abstract Number: 2464 Presented by: MacroGenics, Inc